Keytruda and Bronchitis - a phase IV clinical study of FDA data

Summary:

Bronchitis is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have Lung adenocarcinoma.

The phase IV clinical study analyzes which people have Bronchitis when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Bronchitis?

Bronchitis (inflammation of the mucous membrane in the bronchial tubes) is found to be associated with 2,325 drugs and 2,440 conditions by eHealthMe. Check the latest studies of Bronchitis.

On Jul, 25, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 48 people (0.08%) have Bronchitis.

Among these 48 people:

How long have people been on Keytruda when they have Bronchitis? *

What is the gender of people who have Bronchitis when taking Keytruda? *

female: 47.92 %
male: 52.08 %

What is the age of people who have Bronchitis when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Bronchitis? *

Dyspnea (difficult or laboured breathing): 13 people, 27.08%
Pneumonia: 10 people, 20.83%
Nausea (feeling of having an urge to vomit): 8 people, 16.67%
Constipation: 8 people, 16.67%
Joint Pain: 7 people, 14.58%
Fever: 7 people, 14.58%
Weakness: 6 people, 12.50%
Cough: 5 people, 10.42%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 5 people, 10.42%
Fatigue (feeling of tiredness): 5 people, 10.42%

What are the existing conditions these people have? *

High Blood Pressure: 6 people, 12.50%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 6 people, 12.50%
Endometrial Cancer: 5 people, 10.42%
Lung Cancer - Non-Small Cell (lung cancer): 5 people, 10.42%
Arteriosclerosis Coronary Artery (thickening and hardening of arteries- coronary artery): 3 people, 6.25%
Cancer - Throat Or Larynx: 3 people, 6.25%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 3 people, 6.25%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 6.25%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 4.17%
Dyspnea (difficult or laboured breathing): 2 people, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Bronchitis?

- Check whether Bronchitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Bronchitis treatments and more:

Bronchitis (118,921 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bronchitis:

Bronchitis (2,325 drugs)

Browse all the conditions that are associated with Bronchitis:

Bronchitis (2,440 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.